The global Multiple System Atrophy (MSA) Therapeutics Market is now estimated to increase at a CAGR of 4.4% and be worth US$ 137.3 Million in 2023. Healthcare technology advancements are expected to drive the market to US$ 211.1 million by 2033.The market share for multiple system atrophy is anticipated to increase dramatically, largely as a result of the rise in neurodegenerative illnesses. A new kind of medicine launch is anticipated to lead to growth in the multiple system atrophy market in the approaching years. New players are anticipated to enter the multiple system atrophy throughout the forecast years as a result of the loss of patent protection.
In addition, increasing government support and increasing awareness about neurodegenerative disorders fuel the market growth. The rise in expenditure on healthcare in developing countries and growth in patient awareness of the use of nerve monitoring devices provide new opportunities for the market players.
The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics. For instance, Teva Pharmaceutical Industries Ltd. and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification.
Get a holistic overview of the market from industry experts to evaluate and develop growth strategies. Download the sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16285
North America dominates the multiple system atrophy therapeutics market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.
Key Takeaways from the Market Study
As of 2023, the multiple system atrophy therapeutics market was valued at US$137.3 Million
From 2023 to 2033, the multiple system atrophy therapeutics industry is poised to grow at an 4.4% CAGR
By 2033, the multiple system atrophy therapeutics market is slated to reach a valuation of US$211.1 Million
Based on diagnosis, PET scan segment dominated the market in 2023 with a revenue share of 34.6%.
China is poised to yield a CAGR of 4.1% with respect to multiple system atrophy therapeutics through 2033
“Growing healthcare spending and increase in the prevalence of neurological disorders are expected to radically transform the multiple system atrophy therapeutics market in the coming years,” comments an analyst at FMI.
Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16285
Competitive Landscape
are some of the key players in the chronic smell and flavour loss treatment market like Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. and others.
The manufacturers are involved in the production of multiple system atrophy(MSA) therapeutics larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy(MSA) therapeutics.
In April 2022, ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteinssuch as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS.
In October 2022, Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.
Last few days to get reports at discounted prices, offer expires soon!Request Discount@
https://www.futuremarketinsights.com/request-discount/rep-gb-16285
Key Segments Covered in the Multiple System Atrophy (MSA) Market Industry Survey
Multiple System Atrophy (MSA) Therapeutics Market by Type:
Parkinsonian
Cerebellar
Multiple System Atrophy (MSA) Therapeutics Market by Diagnosis:
Magnetic Resonance Imaging (MRI)
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Tilt Table Test
Others
Multiple System Atrophy (MSA) Therapeutics Market by RegionP:
North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
